DOI:
10.1055/s-00034916
Nervenheilkunde
LinksClose Window
References
Fitzgerald N, Angus K, Elders A. et al
Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.
Addiction 2016;
111: 14477-1487
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.